Pembrolizumab in Neoplasms or Lymphomas

Clinical trial NCT03316573 · SUSPENDED

Trial details

NCT number: NCT03316573
Sponsor: Dana-Farber Cancer Institute
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma Histiocytic Sarcoma Follicular Dendritic Cell Sarcoma Interdigitating Dendritic Cell Sarcoma

Start date: 2017-12-07
Primary completion: 2022-08-18
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.